Instructor Notes — Chapter 37

Internal reference; do not publish.

What this chapter is for

Chapter 37 is the book's reference spine and its calibration instrument. It issues no new ratings. Everything in it was decided in Chapters 2–44; this chapter assembles the decisions so that comparisons become visible that no single chapter could show.

The teaching goal is not coverage of the table. Nobody should be examined on which tier tesamorelin carries. The goal is three transferable moves:

1. Telling an evidence-absent ❌ from an evidence-present-and-negative ❌ (§37.3)
2. Recognizing that a rating attaches to a claim, so one molecule carries many (§37.7)
3. Auditing the direction of one's own errors rather than the count (§37.10)

A student who can do those three and cannot recall a single row has learned the chapter. A student who has memorized eighty rows and cannot do them has not.

Timing and sequencing

Prerequisites are real here. Chapters 5 and 6 must be genuinely in hand — the chapter is unteachable to a group that cannot define a surrogate endpoint or say what makes a trial adequately powered. If the group is shaky, spend fifteen minutes re-establishing Chapter 5's five questions before opening the table.

Suggested allocation (single 90-minute session):

Two-session version: split after §37.8; open session two with Case Study 37.2 and give the drift audit the full hour it deserves. The audit is the highest-value activity in the chapter and it is the first thing that gets cut when time runs short. Protect it.

The cold open that works

Before any framing, put two rows on the board with the ratings hidden:

• BPC-157 accelerates healing of tendon and soft-tissue injuries in humans.
• Infused nesiritide improves death or rehospitalization in adults hospitalized with acute decompensated heart failure.

Ask the room to assign tiers. Almost everyone will assign ❌ to both — correct — and almost everyone, asked which state of knowledge is stronger, will pick BPC-157. Then reveal that one has no completed randomized human trial and the other was tested in roughly 7,100 patients and found not to work.

The inversion is the lesson and it lands better as a discovery than as a definition. Groups that get this wrong out loud remember it; groups that are told it up front nod and forget.

Common misconceptions, in order of frequency

"❌ means it doesn't work." The single most persistent error, and it survives explicit correction. Re-attack it every time it surfaces. ❌ is a statement about the evidence for the claim as usually stated. Several ❌ compounds may be ⚠️ or ✅ in a decade.

"The book is anti-peptide." The 50–50 distribution is the answer and it is worth putting on the board early. Students who came in expecting either a debunking or a defense will misread every block until this is settled.

"The 50–50 tie means peptides are a coin flip." No. It means the ledger is balanced in aggregate, and the structure underneath is the finding: ✅ where trials were funded, ❌ where they were not. Push hard on this; it is the chapter's actual argument and it is the part students skim.

"NOT RATED is the lowest tier." It is not a tier. Use the 🔬 comparison: 🔬 says the answer is coming; NOT RATED says this instrument does not produce that kind of answer.

"A split means the raters hedged." Eight of ten splits are ⚠️/❌ with the same shape — modest version supported, marketing version not. The split is more precise than a single glyph, not less.

"My disagreement means I got it wrong." Explicitly false and worth saying twice. §37.10 and Case Study 37.2's pile-one/pile-two distinction exist for this. A defended ⚠️ against the book's ❌ is correct work.

Handling the room

Someone in the group is taking something in this table. Assume it, in any group of more than about eight. This changes how §37.5's growth-and-repair block should be run: do not turn it into a public verdict on anyone's choices. Keep the discussion on the epistemics — what would have to be true, what evidence would settle it — and let people draw private conclusions. The chapter's own posture (§37.8's safety callout, §37.6's Chapter 39 material) models this: the recommendation is disclosure to a clinician, not abstinence, and never a lecture.

Someone will want the table to say what to do. It does not, and the refusal is pedagogical rather than legal. Redirect to the 💊 In the Clinic callout in §37.5: the table's job is to let a patient arrive with a claim rather than a molecule name.

Someone will want a fifth tier. Take it seriously — it is a good instinct — and then run the §37.4 argument. The desire for the machine to always return something is exactly the reflex the section is inoculating against.

Assessment notes

• Exercises: items marked † require reasoning across the table; expect divergent answers on F, M, O, Q, U, W, Z, AC, AG, AI. Items AE–AH are the drift audit and should be assessed on completeness and honesty, not on match count. Do not grade a low match count as a poor result.
• Quiz: items 1–17 have single correct answers; 18–22 are short answer with a rubric in the key. Item 3 is the discriminator — a student who misses it has not absorbed §37.3.
• Case Study 37.2 is the best single summative assessment in the chapter. Question 6 (right answer for a wrong reason) reliably separates students who understand what the audit measures.